Project Grant HT94252510281
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$450K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas MD Anderson Cancer Center received a $647,995 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on image-guided bidirectional EphB4 agonist-based therapy for ovarian cancer. The award period runs from September 1, 2023 to August 31, 2027. As a leading cancer treatment and research institution, MD Anderson has extensive experience delivering a wide range of cancer-related...
The University of Texas MD Anderson Cancer Center received a $970,734 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from July 1, 2022 to June 30, 2025 to prevent ovarian cancer metastasis by targeting innate and adaptive immunity interactions. A subaward of $97,073 was provided to the University of Texas Health Science Center at Houston to evaluate interleukin-10 expression in mouse and...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
This Project Grant award of $405,000.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Texas MD Anderson Cancer Center to target the novel TXNRD1-cGAS-SASP axis in order to eradicate stem-like cells in epithelial ovarian cancer. The 2-year project aims to transform health care for service members and the public through innovative and impactful cancer research. The University of Texas...
The Defense Health Agency awarded a $1,306,991 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The grant will fund a 4-year research project (8/1/2025 - 7/31/2029) focused on "ORGANOID-BASED MODELING AND THERAPEUTIC TARGETING OF TP53-MUTATED ACUTE MYELOID LEUKEMIA". The research aims to develop innovative approaches for the prevention, diagnosis, and treatment of cancer, with a focus on...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The U.S. Department of the Army Medical Command awarded a $505,071 project grant to The University of Texas MD Anderson Cancer Center under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports a 3-year research project titled "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies." The project aims to investigate innovative approaches to cancer prevention, diagnosis, and...
The U.S. Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $2,429,999 Project Grant to The University of Texas MD Anderson Cancer Center. The award, effective September 15, 2024 through September 14, 2028, will support research focused on the "Detoxification of Environmental Metals to Improve Outcomes in AML." This advanced cancer research initiative aims to investigate innovative approaches to...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $421,204 to The University of Texas MD Anderson Cancer Center to conduct research on "Platelet Pathophysiology in Resistance to Antiangiogenic Therapy Against Ovarian Cancer Evaluated in a Vascularized TME-Chip." The award period runs from August 1, 2024 to July 31, 2028. The research aims to advance understanding of how platelets contribute to...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...